Mydecine Innovations Group™ (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA) is a biotechnology company developing innovative first- and second-generation novel therapeutics for the treatment of mental health and addiction through world-class technology and drug development infrastructure. The company's world-renowned medical and scientific advisory board is progressing a robust research and development (R&D) pipeline of psychedelic derived therapeutics, novel compounds, therapies, and controlled drug delivery systems.
Company Details
- Employees
- 3
- Founded
- -
- Address
- Denver, Co 80211, Us
- in****@****ine.com
- Industry
- Biotechnology
- Website
- mydecine.com
- Keywords
- mycology, fungi, psychedelics, genetics, therapy, telehealth, clinical trials, drug development, Intelectual property, mental health, addiction.
- HQ
- Denver, CO
Mydecine Innovations Group Questions
Mydecine Innovations Group's website is mydecine.com
Mydecine Innovations Group's LinkedIn profile is https://www.linkedin.com/company/mydecine
Mydecine Innovations Group has
3 employees.
View email and phone details for 3
employees at Mydecine Innovations Group.
Mydecine Innovations Group's industry is
Biotechnology
Mydecine Innovations Group's top competitors are
Compass Pathways,
Mindmed,
Cybin Inc,
Seelos Therapeutics, Inc.,
Multidisciplinary Association For Psychedelic Studies (Maps),
Atai Life Sciences,
Field Trip Health (Now Stella Mental Health),
Pan-Biome Pharmaceuticals, Inc,
Numinus,
Mindbloom.
Mydecine Innovations Group's support email address is info@mydecine.com
Mydecine Innovations Group's categories are Biotechnology
Mydecine Innovations Group's founding year is 2020
